Voyageur Pharmaceuticals Ltd. Share Price OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0950 USD | -.--% |
|
-5.00% | -26.98% |
| Market Cap | 2.94Cr 2.07Cr 1.81Cr 1.66Cr 1.55Cr 197.47Cr 2.99Cr 20Cr 7.77Cr 97Cr 7.79Cr 7.62Cr 333.74Cr | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 2.92Cr 2.06Cr 1.8Cr 1.65Cr 1.54Cr 195.92Cr 2.97Cr 20Cr 7.71Cr 96Cr 7.73Cr 7.56Cr 331.13Cr | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,42,35,81,172x |
| Free-Float |
93.03% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | -5.00% | ||
| 1 month | +578.57% | ||
| 3 months | -2.06% | ||
| 6 months | -26.98% | ||
| Current year | -26.98% |
| 1 week | 0.09 | 0.1 | |
| 1 month | 0.02 | 0.2 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 01/07/2019 |
| Director of Finance/CFO | - | 17/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 17/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 06/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 01/07/2019 |
Eric Pommer
CHM | Chairman | - | 30/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -5.00% | - | - | 2.07Cr | ||
| +1.86% | +7.65% | +55.77% | +158.84% | 1,08200Cr | ||
| +3.57% | +7.42% | +69.09% | +58.92% | 63TCr | ||
| +3.99% | +7.37% | +36.87% | +93.77% | 46TCr | ||
| -1.20% | -1.94% | +26.41% | +20.22% | 34TCr | ||
| +4.94% | +3.39% | +39.92% | +28.93% | 30TCr | ||
| +2.42% | +1.60% | +30.06% | +42.24% | 29TCr | ||
| +2.47% | +5.18% | -24.80% | -39.60% | 23TCr | ||
| +3.55% | +6.05% | +26.04% | +68.52% | 20TCr | ||
| +4.21% | +6.00% | +17.72% | +70.33% | 16TCr | ||
| Average | +2.11% | +4.52% | +30.79% | +55.80% | 41.11TCr | |
| Weighted average by Cap. | +1.86% | +5.21% | +41.48% | +80.22% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.78 0.01 0.08 0.03 0.38 0.03 0.03 1.33 |
| Net income | -17.07L -12.04L -10.52L -10L -9L -11Cr -17.36L -1.16Cr -45.06L -5.62Cr -45.19L -44.21L -19Cr | -35.33L -24.9L -21.76L -19.98L -18.63L -24Cr -35.92L -2.41Cr -93.24L -12Cr -93.5L -91.47L -40Cr |
| Net Debt | -1L -79.4T -69.38T -63.71T -59.41T -75.59L -1L -8L -3L -37.08L -3L -3L -1.28Cr | -2L -2L -1L -1L -1L -1.55Cr -2L -15.7L -6L -75.89L -6L -6L -2.62Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | $0.0950 | -.--% | 7,080 |
| 29/26/29 | $0.0950 | +7.71% | 2,920 |
| 26/26/26 | $0.0882 | -11.80% | 36,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















